4basebio UK Societas stock analysis
4basebio UK Societas (88Q) Stock Price & Analysis
88Q Stock Chart & Stats
- Day’s Range
- EUR 5.70 - EUR 5.85
- 52-Week Range
- EUR 4.64 - EUR 9.50
- Previous Close
- EUR 5.85
- Volume
- N/A
- Average Volume (3M)
- 149
- Market Cap
- EUR 120.70M
- Enterprise Value
- EUR 89.85M
- Total Cash (Recent Filing)
- EUR 14.05M
- Total Debt (Recent Filing)
- EUR 23.10M
- Price to Earnings (P/E)
- ―
- Beta
- 0.23
- Next Earnings
- Jun 02, 2027 (Est.)
- EPS Estimate
- -0.7
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Synthetic DNA Positioning
The company is positioned in a specialized enabling segment of biotechnology, supplying synthetic DNA and related capabilities for gene therapies, vaccines, and genetic medicines. This focus gives the business a clear role in supporting biopharma development and manufacturing workflows over the medium term.
Long-term Revenue Expansion
Despite a decline in 2025, the company has expanded revenue over the 2020–2025 period and reports an 81.46% revenue-growth metric. Growth from a small base indicates that its products and capabilities have achieved some commercial scaling, supporting future operating leverage if expansion resumes.
Positive Gross Margin
Positive gross margin indicates that 4basebio captures value above direct production costs, providing an underlying economic contribution from its offerings. Although volatility and high operating costs currently prevent profitability, this gross-profit base could support improved earnings if revenue scales or expenses become more efficient.
Bears Say
Persistent And Widening Losses
The combination of declining 2025 revenue and materially wider losses shows that the business has not yet converted its technology and revenue base into sustainable profitability. Negative operating and net margins leave limited internal funding capacity and make earnings improvement dependent on renewed growth or cost control.
Accelerating Cash Burn
Persistent negative operating and free cash flow means the company is consuming cash rather than self-funding operations. The acceleration in 2025 increases the importance of revenue scaling, expense reductions, or external financing, and can constrain investment in product development and manufacturing capabilities.
Deteriorating Balance Sheet
Higher debt alongside sharply lower equity weakens financial flexibility and increases the burden placed on a loss-making business. Declining assets and elevated debt-to-equity can restrict capital-allocation options, while continued losses could increase dilution or funding pressure if external capital is required.
4basebio UK Societas News
88Q FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
What is 4basebio UK Societas’s market cap?
When is 4basebio UK Societas’s upcoming earnings report date?
How were 4basebio UK Societas’s earnings last quarter?
Is 4basebio UK Societas overvalued?
Does 4basebio UK Societas pay dividends?
What is 4basebio UK Societas’s EPS estimate?
How many shares outstanding does 4basebio UK Societas have?
What happened to 4basebio UK Societas’s price movement after its last earnings report?
Which hedge fund is a major shareholder of 4basebio UK Societas?
What is the TipRanks Smart Score and how is it calculated?
4basebio UK Societas Stock Smart Score
Company Description
4basebio UK Societas
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Amy Jo Walker
- Employees
- 140
- Website
- www.4basebio.com
- Address
- 25 Norman Way, Cambridge, CAM, CB24 5QE, GB
4basebio UK Societas (88Q) Earnings & Revenues
88Q Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 1 | 0 | 11 |









